Wang Q, Wang J, Mathur R, Youngblood M, Jin Q, Hou Y
Sci Adv. 2025; 11(11):eadn2830.
PMID: 40073147
PMC: 11900876.
DOI: 10.1126/sciadv.adn2830.
Voena C, Ambrogio C, Iannelli F, Chiarle R
Nat Rev Cancer. 2025; .
PMID: 40055571
DOI: 10.1038/s41568-025-00797-9.
Wei Z, Gong B, Li X, Chen C, Zhao Q
BMC Cancer. 2024; 24(1):1279.
PMID: 39407175
PMC: 11481459.
DOI: 10.1186/s12885-024-13044-5.
Hailey D, Kanjilal D, Koulen P
Int J Mol Sci. 2024; 25(18).
PMID: 39337590
PMC: 11432750.
DOI: 10.3390/ijms251810105.
Lai W, Chuang T, Borenas M, Lind D, Hallberg B, Palmer R
Cell Death Differ. 2024; 31(7):910-923.
PMID: 38858548
PMC: 11239919.
DOI: 10.1038/s41418-024-01319-0.
ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition.
Borenas M, Umapathy G, Lind D, Lai W, Guan J, Johansson J
Proc Natl Acad Sci U S A. 2023; 121(1):e2315242121.
PMID: 38154064
PMC: 10769851.
DOI: 10.1073/pnas.2315242121.
Telomere Maintenance Mechanisms in a Cohort of High-Risk Neuroblastoma Tumors and Its Relation to Genomic Variants in the and Genes.
Djos A, Thombare K, Vaid R, Gaarder J, Umapathy G, Reinsbach S
Cancers (Basel). 2023; 15(24).
PMID: 38136279
PMC: 10741428.
DOI: 10.3390/cancers15245732.
Multifaceted Roles of ALK Family Receptors and Augmentor Ligands in Health and Disease: A Comprehensive Review.
Katic L, Priscan A
Biomolecules. 2023; 13(10).
PMID: 37892172
PMC: 10605310.
DOI: 10.3390/biom13101490.
IGF1R Contributes to Cell Proliferation in -Mutated Neuroblastoma with Preference for Activating the PI3K-AKT Signaling Pathway.
Guan J, Borenas M, Xiong J, Lai W, Palmer R, Hallberg B
Cancers (Basel). 2023; 15(17).
PMID: 37686528
PMC: 10563084.
DOI: 10.3390/cancers15174252.
Bioinformatics analysis of miRNAs in the neuroblastoma 11q-deleted region reveals a role of miR-548l in both 11q-deleted and MYCN amplified tumour cells.
Jurcevic S, Keane S, Borgmastars E, Lubovac-Pilav Z, Ejeskar K
Sci Rep. 2022; 12(1):19729.
PMID: 36396668
PMC: 9671919.
DOI: 10.1038/s41598-022-24140-6.
Chromosome 11q loss and amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma.
Keller K, Eleveld T, Schild L, van den Handel K, van den Boogaard M, Amo-Addae V
Front Oncol. 2022; 12:929123.
PMID: 36237330
PMC: 9552537.
DOI: 10.3389/fonc.2022.929123.
A Deficiency of the Psychiatric Risk Gene DLG2/PSD-93 Causes Excitatory Synaptic Deficits in the Dorsolateral Striatum.
Yoo T, Joshi S, Prajapati S, Cho Y, Kim J, Park P
Front Mol Neurosci. 2022; 15:938590.
PMID: 35966008
PMC: 9370999.
DOI: 10.3389/fnmol.2022.938590.
Inflammation suppresses DLG2 expression decreasing inflammasome formation.
Keane S, Herring M, Rolny P, Wettergren Y, Ejeskar K
J Cancer Res Clin Oncol. 2022; 148(9):2295-2311.
PMID: 35499706
PMC: 9349146.
DOI: 10.1007/s00432-022-04029-7.
Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer.
Hao Y, He B, Wu L, Li Y, Wang C, Wang T
Nat Commun. 2022; 13(1):1974.
PMID: 35418124
PMC: 9007954.
DOI: 10.1038/s41467-022-29585-x.
Silencing of AKIP1 Suppresses the Proliferation, Migration, and Epithelial-Mesenchymal Transition Process of Glioma Cells by Upregulating DLG2.
Chen Z, Wen H, Zhang J, Zou X, Wu S
Biomed Res Int. 2022; 2022:5648011.
PMID: 35111846
PMC: 8803424.
DOI: 10.1155/2022/5648011.
Chromosome Imbalances in Neuroblastoma-Recent Molecular Insight into Chromosome 1p-deletion, 2p-gain, and 11q-deletion Identifies New Friends and Foes for the Future.
Guan J, Hallberg B, Palmer R
Cancers (Basel). 2021; 13(23).
PMID: 34885007
PMC: 8657310.
DOI: 10.3390/cancers13235897.
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models.
Szydzik J, Lind D, Arefin B, Kurhe Y, Umapathy G, Siaw J
Nat Commun. 2021; 12(1):6813.
PMID: 34819497
PMC: 8613282.
DOI: 10.1038/s41467-021-27057-2.
Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer.
Wulf A, Moreno M, Paka C, Rampasekova A, Liu K
Int J Mol Sci. 2021; 22(21).
PMID: 34769149
PMC: 8584162.
DOI: 10.3390/ijms222111718.
Neuroblastoma xenograft models demonstrate the therapeutic potential of Lu-octreotate.
Romiani A, Spetz J, Shubbar E, Lind D, Hallberg B, Palmer R
BMC Cancer. 2021; 21(1):950.
PMID: 34433438
PMC: 8386073.
DOI: 10.1186/s12885-021-08551-8.
Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells.
Siaw J, Gabre J, Uckun E, Vigny M, Zhang W, Van den Eynden J
Cancers (Basel). 2021; 13(8).
PMID: 33921066
PMC: 8071449.
DOI: 10.3390/cancers13081909.